B. Afzelii Antigen Panel for Early Lyme Disease Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for Lyme disease, particularly in early stages and for the B. afzelii species, suffer from low sensitivity and specificity, failing to accurately detect the infection in a significant portion of patients.
Innovation Solution
The use of novel antigenic proteins from B. afzelii, such as D0016, A0029, and A0001, with high identity to sequences SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6, or antigenic fragments, for detecting antibodies in blood samples, enhancing sensitivity and specificity in early Lyme disease detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional antigens (VlsE C6 region, OspC C10 peptide) are used in serological testing, then specificity is improved, but sensitivity in early infection deteriorates
Solution Approach 1:
The patent segments the Borrelia proteome into multiple antigenic regions, selecting specific protein domains (D0016, A0029, A0001) that are optimally immunogenic in early infection. This segmentation allows targeting of specific antigenic epitopes that conventional tests miss, thereby improving sensitivity while maintaining specificity through selective antigen usage.
Solution Approach 2:
The patent changes the antigenic parameters by using recombinant proteins with high sequence identity to specific Borrelia afzelii protein sequences (at least 90% identity). This parameter change in antigen selection enables detection of early infection antibodies that conventional antigens cannot detect, resolving the sensitivity-specificity tradeoff.
2Measurement precision
If two-tier testing methodology is used, then diagnostic accuracy is improved for late disease, but sensitivity in early localized disease deteriorates
Solution Approach 1:
The patent performs preliminary action by using antigens that elicit antibody responses early in the infection process. The selected antigens (D0016, A0029, A0001) are recognized by antibodies produced during early infection, enabling detection before the classic two-tier methodology becomes reliable, thus improving early disease sensitivity.
Solution Approach 2:
The patent creates a simplified single-tier diagnostic system that copies the effectiveness of complex multi-tier approaches by using a panel of highly specific antigens. This single-tier approach with optimized antigens achieves the diagnostic accuracy of two-tier methods for early disease, eliminating the sensitivity loss associated with conventional two-tier testing.
3Ease of operation
If standard testing algorithms are used, then ease of operation is maintained, but measurement precision for early disease deteriorates
Solution Approach 1:
The patent achieves universality by developing a single-tier test system that can detect early, localized, and disseminated Lyme disease using the same antigen panel. This multi-functional test maintains ease of operation while improving measurement precision for early disease, as the same simple procedure works across all disease stages with the optimized antigen selection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antigens provide unprecedented sensitivity and specificity for early Lyme disease detection, surpassing existing methods, with sensitivity of at least 80% and specificity of at least 90%, and are suitable for all stages of Lyme disease.
Implementation Method 1
The use of novel antigenic proteins from B. afzelii, such as D0016, A0029, and A0001, with high identity to sequences SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6, or antigenic fragments, for detecting antibodies in blood samples
Data Source
AI summary
Selected Antigens for early detection of Lyme disease are presented, and particularly for Lyme disease caused by B. afzelii. Advantageously, these antigens allow for unprecedented and unexpectedly high sensitivity and specificity in detection of early Lyme disease.